Key facts
- This page summarizes Lauren Merendino's Form 4 filing for Day One Biopharmaceuticals, Inc. (DAWN).
- 9 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 18 Feb 2026, 17:18.
Lauren Merendino - 15 Feb 2026 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- DAWN
- Reported as of
- 15 Feb 2026
- Net transaction value
- -$67,448
- SEC form
- 4
- Accepted by SEC
- 18 Feb 2026, 17:18:49 UTC
- Prior SEC filing
- 30 Jan 2026
- Next SEC filing
- 23 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Charles N. York II, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Lauren Merendino filed Form 4 for Day One Biopharmaceuticals, Inc. (DAWN) on 18 Feb 2026.
Change
- Previous filing in this sequence was filed on 30 Jan 2026.
- Current net transaction value: -$67,448.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001855298
Primary reporting owner
Merendino Lauren
- Relationship
- Chief Commercial Officer
- Address
- 1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
- Signature
- /s/ Charles N. York II, as Attorney-in-Fact
- Signature date
- 18 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DAWN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,162
- Change %
- +6.2%
- Price
- Shares after
- 53,971
- Date
- 15 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
DAWN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,688
- Change %
- +6.8%
- Price
- Shares after
- 57,659
- Date
- 15 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
DAWN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,687
- Change %
- +6.4%
- Price
- Shares after
- 61,346
- Date
- 15 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
DAWN
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,625
- Change %
- +7.5%
- Price
- Shares after
- 65,971
- Date
- 15 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
DAWN
transaction
Common Stock
Sale
- Transaction value
- $67,448
- Shares
- -5,814
- Change %
- -8.8%
- Price
- $11.60
- Shares after
- 60,157
- Date
- 17 Feb 2026
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DAWN
transaction
Derivative
Restricted Stock Unit (RSU)
Options Exercise
- Transaction value
- $0
- Shares
- -3,162
- Change %
- -14%
- Price
- $0.000000
- Shares after
- 18,978
- Date
- 15 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,162
- Exercise price
- Footnotes
- F1, F4, F5
DAWN
transaction
Derivative
Restricted Stock Unit (RSU)
Options Exercise
- Transaction value
- $0
- Shares
- -3,688
- Change %
- -12%
- Price
- $0.000000
- Shares after
- 25,816
- Date
- 15 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,688
- Exercise price
- Footnotes
- F1, F5, F6
DAWN
transaction
Derivative
Restricted Stock Unit (RSU)
Options Exercise
- Transaction value
- $0
- Shares
- -3,687
- Change %
- -8.3%
- Price
- $0.000000
- Shares after
- 40,565
- Date
- 15 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,687
- Exercise price
- Footnotes
- F1, F5, F6
DAWN
transaction
Derivative
Restricted Stock Units (RSU)
Options Exercise
- Transaction value
- $0
- Shares
- -4,625
- Change %
- -6.2%
- Price
- $0.000000
- Shares after
- 69,375
- Date
- 15 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,625
- Exercise price
- Footnotes
- F1, F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
Footnote F2
The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $11.195 to $11.8508, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade.
Footnote F4
The RSUs vested as to 1/4th of the total award on August 15, 2024, and the remaining 3/4 of the award vests in 12 substantially equal quarterly installments thereafter on November 15, February 15, May 15 and August 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Footnote F5
RSUs do not expire; they either vest or are canceled prior to the vesting date.
Footnote F6
The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.